期刊
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
卷 16, 期 7, 页码 789-799出版社
BENTHAM SCIENCE PUBL
DOI: 10.2174/1871527315666161213110104
关键词
Desmoteplase; ischemic stroke; mortality; meta-analysis; reperfusion; tissue plasminogen activator
资金
- Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [16H05844]
- Japan Initiative for Global Research Network on Infectious Diseases (J-GRID)
- Grants-in-Aid for Scientific Research [16H05844] Funding Source: KAKEN
Introduction: There is an unmet need to develop better treatments for acute ischemic stroke (AIS). Desmoteplase is a vampire bat saliva-derived analogue of human tissue plasminogen activator. It has higher fibrin selectivity and a longer half-life, compared to alteplase. We performed this meta-analysis to investigate the safety and efficacy of desmoteplase in AIS. Method: A computer literature search (PubMed, EMBASE, CENTRAL, Scopus, Web of science, and clinicaltrials.gov) was carried out. Data were extracted from eligible records and analyzed using RevMan software (version 5.3 for windows). Safety and efficacy endpoints were pooled as odds ratios (ORs) for the two groups. Result: Five randomized trials (n= 821 patients) were pooled in the final analysis. The overall effect size favored desmoteplase over placebo in terms of reperfusion 4 to 24 hours posttreatment (OR 1.49, 95% CI [1.02, 2.19]). However, the pooled effect size did not favor either of the two groups in terms of good clinical outcome at 90 days (OR 1.16, 95% CI [ 0.86, 1.55]). Neither of the primary safety outcomes differed significantly between the two groups (symptomatic intracranial hemorrhage: OR 1.29, 95% CI [0.53, 3.16] and mortality within 90 days: OR 1.20, 95% CI [0.73, 1.97]). Conclusion: Current evidence suggests a favorable reperfusion effect for desmoteplase within 3 to 9 hours after AIS. Further large randomized trials, using a moderate dose between 90 mu g/kg and 125 mu g/kg, are required to translate this successful reperfusion into better clinical and quality of life outcomes for AIS patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据